Guardant Health soars 21% on upbeat Q3, raised outlook
Guardant Health shares jumped 21% in after-hours trade after posting 39% YoY revenue growth to $265.2 million in Q3, driven by strong gains in oncology, screening, and biopharma. The company raised its 2025 revenue outlook to as high as $970 million. The company reported a non-GAAP gross margin of 66%, up from 63% in the same period last year.